Sangamo Gets Fast Track Designation For SB-525 Hemophilia A Gene Therapy – Nasdaq
|
Sangamo Gets Fast Track Designation For SB-525 Hemophilia A Gene Therapy
Nasdaq (RTTNews.com) – Sangamo Therapeutics Inc. ( SGMO ) said Tuesday that the U.S. Food and Drug Administration has granted Fast Track designation to SB-525, the Company's clinical stage cDNA gene therapy candidate for hemophilia A, which is being … |
